Objective To explore the clinical effect of enalapril and tripterygium glycosides in the treatment of diabetic nephropathy. Methods: A total of 80 patients with diabetic nephropathy who were admitted to our hospital from May 2021 to May 2022 were divided into a control group (enalapril treatment, n=40 cases) and a research group (enalapril and Tripterygium Glycosides combined treatment, n=40 cases) according to the random number table. The treatment effects were compared, and the 24h urine protein volume, urinary albumin excretion rate, renal function indicators and inflammatory factor indicators of the patients before and after treatment were evaluated. Results: The total effective rate of treatment group was 93.33％, which was higher than that of control group (P＜0.05). The volume of urine protein and the excretion rate of microalbumin in 24h after treatment were (1.35±0.26) g, (465.36±50.63)mg/d/d, respectively, which were lower than those in the control group (P＜0.05). Besides, the levels of Scr and Cys-C in the treatment group were (80.04±8.18) μ mol/L and (0.65±0.05)mg/L/L, respectively, lower than those in the control group (P＜0.05). Besides, the levels of CRP and TNF-α in the study group after treatment were (9.49±1.07)mg/L/L, (3.01±0.31)ng/ml/mL, which were also lower than those in the control group (P＜0.05). Conclusion: The combined use of enalapril and Tripterygium Glycosides in the treatment of diabetic nephropathy has reliable clinical effects. It can reduce the 24h urine protein and urinary albumin excretion rate, improve renal function and reduce inflammatory factors, which is worthy of promotion.
万方数据